Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

[1] Koike R(2009)Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis Mod Rheumatol. 19 351-7

[2] Harigai M(2007)Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis Mod Rheumatol. 17 451-8

[3] Atsumi T(2006)Guidelines for the proper use of etanercept in Japan Mod Rheumatol. 16 63-7

[4] Amano K(2010)Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis J Inflamm (Lond) 7 41-507

[5] Kawai S(2012)Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med. 367 495-905

[6] Saito K(2009)The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum. 60 1895-29

[7] Koike R(2012)Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum. 64 617-81

[8] Takeuchi T(2012)A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis Rheum. 64 970-60

[9] Eguchi K(2013)Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet. 381 451-19

[10] Miyasaka N(2012)Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N Engl J Med. 367 508-61

[1] Koike R(2009)Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis Mod Rheumatol. 19 351-7

[2] Harigai M(2007)Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis Mod Rheumatol. 17 451-8

[3] Atsumi T(2006)Guidelines for the proper use of etanercept in Japan Mod Rheumatol. 16 63-7

[4] Amano K(2010)Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis J Inflamm (Lond) 7 41-507

[5] Kawai S(2012)Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med. 367 495-905

[6] Saito K(2009)The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum. 60 1895-29

[7] Koike R(2012)Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum. 64 617-81

[8] Takeuchi T(2012)A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis Rheum. 64 970-60

[9] Eguchi K(2013)Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet. 381 451-19

[10] Miyasaka N(2012)Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N Engl J Med. 367 508-61